|
全国免费电话:400-668-6834 -- 仅限中国地区 -- |
在线订购:QQ: 4006686834 电话订购:021-68591985 邮件订购:info@selleck.cn 我们也提供销售人员上门服务 |
技术支持电话:400-168-6834 我们将于一个工作日与您联系 |
目录号:D4001 批次号: D400106
Trastuzumab deruxtecan (DS-8201a, T-DXd) 是一种抗体药物偶联物 (antibody-drug conjugate,ADC),由抗 HER2(人表皮生长因子受体 2)抗体和细胞毒性拓扑异构酶 I 抑制剂组成。Trastuzumab deruxtecan 显示出持久的抗肿瘤活性。Trastuzumab deruxtecan分子量为153KDa。
| CAS号 | 1826843-81-5 |
|---|---|
| 分子量 | 153000 |
| 配置 | 100 mM Pro-Ac, 20 mM Arg, pH 5.0 |
| DAR | 7.8 |
| ADC antiody | Trastuzumab |
| ADC cytotoxin | DXd |
| 纯度 | 99% |
| 蛋白浓度 | 7.769mg/ml |
| 内毒素 | <1EU/mg |
| LINC01235 Promotes Clonal Evolution through DNA Replication Licensing-Induced Chromosomal Instability in Breast Cancer [ Advanced Science, 2025, 2413527] | PubMed: 39950924.0 |
| Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer [ JCI Insight, 2025, e187151] | PubMed: 40857406.0 |
| Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer [ JCI Insight, 2025, 10(16)e187151] | PubMed: 40857406 |
禁止用于人体及治疗!